Register for our free email digests:
Latest From AbbVie Inc.
Analysts predict that Sanofi and Regeneron's Dupixent is going to dominate the severe eczema market but the oral options of Lilly/Incyte's baricitinib and AbbVie's upadacitinib are progressing through the pipeline to make a challenge.
Top-line MURANO data support Venclexta's current conditional approvals and expand its use into a broader population that should radically boost sales.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Janssen-Cilag/MorphoSys's potential first-in-class psoriasis therapy has received a positive approval recommendation from Europe's top scientific advisory panel, and could become a blockbuster product despite the cluttered and changeable state of the dermatology sector.
- Therapeutic Areas
- Gynecological, Urological
- Immune Disorders
- Infectious & Viral Diseases
- Metabolic Disorders
- Neurology, Nervous System
- Renal System
- North America
- Company Type
- Big Pharma
- Parent & Subsidiaries
- AbbVie Inc.
- Senior Management
Richard A Gonzalez, Chmn. & CEO
William J Chase, EVP, CFO
Michael Servino, MD, EVP, R&D & CSO
Carlos Alban, EVP, Commercial Ops.
- Contact Info
Phone: (847) 937-6100
1 N. Waukegan Rd.
North Chicago, IL 60064
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.